Background: Nausea, vomiting, and constipation (OIC) are common adverse effects of
| INTRODUCTION
Opioids are the most commonly used prescription analgesics, with a trend toward increased use over time, for both acute and chronic pain.
1,2 Symptoms associated with gastrointestinal dysmotility including nausea, vomiting, and constipation are common adverse effects of acute and chronic opioid use. [3] [4] [5] The effects of opioid agonists on gastrointestinal motility have been studied extensively; morphine was shown to cause a migrating phasic activity mimicking phase III of interdigestive migrating motor complex in the human small intestine. 6 By reducing colonic tone, morphine leads to an increase in storage capability, and slower colonic transit, 7 and a decreased number of bowel movements. 8 Through their opioid agonist effect on μ and δ receptors, synthetic beta-endorphins lead to a dose-related increase in pyloric phasic pressure activity and induction of intestinal bursts of rhythmic activity, which interrupt normal postprandial motility in healthy individuals. 9 Lembo et al 10 showed that the μ-opioid agonist, fentanyl, inhibits the perception of phasic rectal distention in a dose-dependent fashion. In addition, activation of μ and δ opioid receptors reduces active Cl − secretion and passive water movement into the colonic lumen by inhibiting submucosal secretomotor neurons, which can result in stool of more solid consistency.
11
Peripherally active μ-opioid receptor antagonists (PAMORA) have emerged as a treatment option for chronic opioid-induced constipation (OIC). 12 Naloxegol is a novel PAMORA which is efficacious in the treatment of chronic OIC when administered orally at a dose of 25 mg daily. 13 It is a polyethylene glycol derivative of naloxol, with significantly less central nervous system (CNS) penetration compared with naloxol.
14
There are clinical situations when reversal of the motility effects of μ-opioids could benefit patients who are receiving such medications for a short term, typically for an acute indication. Such patients would be regarded as opioid-naïve. However, the optimal doses of PAMORAs for such indications and the effects of a PAMORA, naloxegol, at the highest dose, 25 mg daily approved for use in patients, 15 on gastrointestinal and colonic transit retarded by concomitant codeine treatment in opioid-naïve individuals are unclear.
Our study hypothesis is that the approved 25 mg daily dose of naloxegol reverses the pan-gut transit retardation induced by codeine.
Our aim was to compare the effects on gastrointestinal and colonic transit of treatment with codeine, naloxegol, or combination of both, compared with placebo, in healthy volunteers.
| METHODS

| Participants
We conducted a randomized, double-blind, placebo-controlled, 
| Randomization
Individuals were randomized (based on computer-generated random sequence without restrictions or stratifications provided by the office of the study statistician) to the following 4 treatment groups,
Key Points
State of current knowledge Research Pharmacy; all participants and study staff were blinded until all data were locked and analyzed by the study statistician. Allocation was concealed throughout the study, as the randomization code was only available to the research pharmacist who was located in another section of Mayo Clinic, not in the Clinical Research Unit. All participants, study staff and nurses were blinded to study intervention, as the intervention was coded with a study number.
| Experimental design
The experimental design is shown in Figure 1 .
Participants were enrolled by the study coordinators and received the study medications from the research pharmacy (not from the study staff) for 3 days starting on day 0 of the study, and underwent detailed scintigraphic testing over 48 hours (starting on day 1).
| Measurement of pan-gastrointestinal transit
A capsule containing n 111 InCl 3 -labeled activated charcoal particles was used for colonic transit assessment, and a 99m Tc-labeled egg meal (296 kcal, 32% fat) was used to assess gastric emptying (GE) and small bowel transit. After ingestion of the radiolabeled meal on day The following transit parameters were computed: GE T 1/2 , colonic filling at 6 hours (CF6, a surrogate for combined GE and small bowel transit), colonic GC at 24 and 48 hours, and ascending colon emptying (ACE) T 1/2 . All participants underwent an initial medical evaluation during the screening period (within 4 weeks prior to day 0) and a subsequent medical evaluation including assessment for medication compliance and adverse events (AE) upon completion of the study on day 3.
| Outcome measures
The primary outcome measures were GE T 1/2 , colonic filling (%) at 6 hours, and overall colonic transit summarized as GC at 24 hours.
The secondary outcome measures were colonic transit summarized by GC at 4 and 48 hours, ACE T 1/2 , and percent of standardized meal remaining in the stomach at 2 and 4 hours.
| Statistical analysis
This analysis was conducted with 18 participants per group, except for the codeine-placebo group which consisted of 17 subjects. The analysis was by originally assigned groups and was based on intentionto-treat principles, based on all of the data acquired during the study and with no data imputation. The primary and secondary endpoints were analyzed using a one-way analysis of variance on ranks in view of skewed data distribution. Comparisons between 2 groups were conducted using Mann-Whitney U test.
| Statistical power with sample size in each group
The sample size (N = 18 per treatment group) provided 80% power to detect the effect sizes listed below for the specific treatment group contrast, assuming the (pooled) variance is known. An analysis of variance provides an estimate of this (pooled) variance based on 68 degrees of freedom. The coefficients of variation and corresponding standard deviation are from recent studies in healthy volunteers using the same measurement methodology [18] [19] [20] [21] [22] (see Table 1 ).
The magnitude of change detectable is considered clinically relevant. For example, ~30-minute difference in GE that could be detected between treatment groups would be clinically relevant, since it would be associated with a difference in 100 kcal ingested at a buffet meal, or 150 kcal ingested to achieve fullness in a laboratory-based nutrient drink test. 23 Similarly, prior studies showed that a decrease in colonic transit GC of 0.97 units at 24 hours is associated with a change in stool consistency of ~0.6 units on the Bristol stool form scale and ~0.5 stools per day, 24 while an increase of the colon GC24 of 1.8 GC units is associated with significant diarrhea, as in carcinoid syndrome.
25 Table 1 shows the minimum effect sizes that could be detected with the stated power; larger differences observed would even provide higher clinical effects. Table 2 , which shows there were no significant differences in the 4 groups. All the participants who were T A B L E 1 Estimated effect size detectable based on n = 18 subjects per group F I G U R E 2 CONSORT flow chart of participant disposition randomized received intended treatment (except 1 patient who dropped out during day 1 of dosing), and all their data were analyzed for primary and secondary outcomes. One participant (randomized to codeine and placebo) dropped out of the study during the first day of dosing and no measurements were obtained.
| RESULTS
| Participants
| Effects on gastric and small bowel transit
All transit data are provided in Table 3 .
There was non-significant overall difference in GE T 1/2 between the 4 groups (P = .066). As expected, codeine numerically retarded GE There was a significant overall group difference in percent colonic filling at 6 hours (CF6) (P = .023), with significant difference (P = .019)
between CP (11.0% filling at 6 hours, 0.0-45.0%) and NP (51%, 18.8-76.2%) (Figure 4 ).
Note that, with reference to the primary aim of the study, there
were no significant differences in GE T 1/2 and CF6 between CN and IQR = interquartile range; GE = gastric emptying; CF = colonic filling; GC = geometric center; ACE = ascending colon emptying.
F I G U R E 3
Analysis of variance of the lag time and gastric emptying (GE) T 1/2 among the 4 groups: codeine-naloxegol, codeine-placebo, naloxegol-placebo, placebo-placebo. M-W = Mann-Whitney U test CP groups, indicating that naloxegol did not reverse the effects of codeine at the dosages administered.
| Colonic transit and evaluation of effect of naloxegol on retardation of gut transit by codeine
There were no significant differences in GC at 24 or 48 hours between CP and CN groups ( Figure 5 ). As expected, codeine significantly retarded colonic transit and ACE T 1/2 ( Figure 6 ). Naloxegol did not accelerate colonic transit relative to codeine-treated groups.
| Adverse effects
No serious AE were reported, and there was no significant difference in the rate of occurrence of individual AEs between the 4 groups ( Table 4 ). The most commonly reported AEs were constipation (n = 21), nausea (n = 14), headache (n = 14), fatigue (n = 11), and dizziness (n = 9). The 4-group comparisons for constipation and nausea
were not significant (P = .094 and .069, respectively) though they appeared to be numerically higher with codeine treatment.
| DISCUSSION
In opioid-naïve healthy volunteers without OIC or constipation, the short-term administration of codeine retards transit pan-gut transit compared with placebo, and numerically but not significantly (P = .083) slows GE compared with placebo. However, naloxegol, 25 mg daily, does not reverse the retardation of small bowel or colonic dose. 27 The half-maximal effect (iAUC50) of naloxegol effects on orocecal transit times (OCTT) was observed at plasma concentrations associated with doses of 15-30 mg naloxegol. 27 However, this effect was observed with transit of lactulose, a liquid substrate rather than solids, and it is clear that opioid-induced disturbances of solid transit through the stomach and colon, in particular, are the most relevant.
The OCTT with lactulose does not test either of these functions.
Higher doses of naloxegol, therefore, may be needed to prevent or treat constipation resulting from acute administration of narcotic analgesics. Further studies with naloxegol at higher dose are warranted to assess its ability to reverse the retardation of GI transit caused by acute administration of codeine. An example of clinical applicability of this approach, if proven effective in acute pain, would be to start an appropriate dose of naloxegol prior to narcotics following a surgical procedure known to cause significant pain, such as orthopedic surgeries, when opioid analgesics are contemplated. However, higher doses are not currently approved for use in human subjects.
We ensured that the duration of administration of naloxegol was sufficient to achieve pharmacological activity, since naloxegol is rapidly absorbed with mean time to maximum plasma concentration of <2 hours, and following once-daily administration, steady state is achieved within 2-3 days. 13 Despite the limited efficacy of the dose used in this study when administered short term, naloxegol offers the advantage of an oral administration with minimal CNS penetration, thus preserving centrally mediated analgesia delivered by opioid receptor agonists. 14 Our study and prior studies 28 Similarly, alvimopan was shown to be effective at treating OIC in patients with chronic non-cancer pain on narcotics at doses as low as of 0.5 mg orally bid, 32 whereas a higher dose (12 mg orally bid) was used to reverse codeine's inhibitory effect on colonic and small bowel transit in healthy opioid-naïve volunteers receiving a short course of codeine. 33 Repeated opioid administration may lead to opioid receptor downregulation or decoupling from their downstream intracellular signaling activity, leading to the need for higher dosage of agonist to achieve the same analgesic effect and, possibly, a lower dosage of μ-opioid antagonist to reverse the effect of chronic μ-opioid treatment.
An alternative hypothesis is that the effects of opioid agonists are more pronounced in opioid-naïve individuals, leading to more solid consistency of intraluminal content and slower transit. These effects may be more difficult to reverse by opioid antagonists in an acute setting.
These observations, including our results, carry important clinical implications, as they further clarify the physiologic mechanism of action of PAMORAs in different clinical scenarios. The data suggest that a higher dose may indeed be needed for opioid-naïve patients who develop bowel dysfunction secondary to a new exposure to opioid analgesics. Thus, PAMORAs, including naloxegol, may be beneficial to prevent and treat constipation in these patients, if the appropriate higher dose is used. Furthermore, the risk of opioid withdrawal, which is small when PAMORAs are used, is likely to be even smaller in opioid-naïve individuals receiving a short course of narcotics, and higher doses of PAMORAs may be safe.
There are many strengths in this study including the randomized, double-blind, placebo-controlled, single-center, parallel-group study design; the use of a clinically relevant dose of codeine (30 mg qid) ; and the use of the gold standard (scintigraphy) to assess GI and colonic transit. These attributes suggest that the data are generalizable to healthy, opioid-naïve people. In addition, the dose of codeine administered was associated with a ~30-minute difference in GE T 1/2 and a difference in GC24 of 0.9
GC unit, compared with placebo. Therefore, the study was appropriately powered to be able to detect pharmacodynamics effect of codeine and, potentially, the reversal or inhibition of these effects by naloxegol.
Limitations include the use of a relatively low opioid agonist dose, compared to the typical doses used in clinical practice to treat acute pain in opioid-naïve patients. In addition, the study lacks data on the effect of naloxegol use beyond 3 days and the effects of different doses of naloxegol. Our current study was also limited by the dose approved for use in human subjects, but it provided the important information that, at this highest approved dose, naloxegol was not effective in reversing the inhibition of pan-gut transit resulting from the use of an opioid at standard, clinically applicable doses. Therefore, future studies are needed to assess the effects of higher naloxegol doses and different treatment durations on the GI transit altering the effect of opioid agonists in patients who are opioid-naïve, as well as in subjects on high-dose opioids chronically for a single condition.
| CONCLUSION
In opioid-naïve healthy volunteers without OIC or constipation, the short-term administration of naloxegol (25 mg/day) accelerates gastric and small bowel transit compared with codeine, which retards transit compared with placebo. However, naloxegol, 25 mg/day, does not reverse the retardation of gastric, small bowel or colonic transit induced by acute administration of codeine, 30 mg qid. Further studies with naloxegol at higher dose are warranted to assess the ability to reverse the retardation of transit caused by acute administration of codeine.
ACKNOWLEDGMENT
The authors thank Mrs. Cindy Stanislav for excellent secretarial assistance.
DISCLOSURES
Dr. Camilleri has served as a consultant (with the consulting fee going to his employer, Mayo Clinic) for AstraZeneca. The other authors have no personal interests to declare.
GUARANTOR OF THE ARTICLE
Dr. Michael Camilleri takes responsibility for the integrity of this work as a whole, from inception to published article. 
